USFDA issues Form 483 with 5 procedural observations after Ambernath plant inspection
USFDA did an unannounced inspection at the Ambernath plant from 21 October 2026 to 29 October 2026.
By ScoutQuest · · 2 min read
- Inspection period
- 21 October 2026 to 29 October 2026
- Form 483 observations
- 5 observations: 3 on system improvement and 2 on the product application under review
- Observation nature
- All 5 are procedural and do not relate to data integrity
What the company informed the exchanges
Rubicon Research told BSE and NSE that the United States Food and Drug Administration carried out an unannounced inspection at its Ambernath, Maharashtra manufacturing facility from 21 October 2026 to 29 October 2026. The inspection was triggered by a product update and was described as a comprehensive GMP inspection in addition to the product application under review.
What was issued at the end
- A Form 483 was issued on conclusion of the inspection.
- It contains 3 observations with respect to system improvement and 2 observations with respect to the product application under review.
- The company states that all 5 observations are procedural in nature and do not relate to data integrity.
Status of the company's operational facilities, as summarised by the company
- R&D Canada, Apr-26, unannounced: zero observations, EIR received.
- R&D Thane, Mar-25, announced: zero observations, EIR received.
- Manufacturing New Jersey, USA, May-26, inspection held prior to the company's acquisition: six observations recorded during the inspection under the previous owner, EIR received with VAI status.
- Manufacturing Ambernath, Oct-26, unannounced: 3 observations on system improvement and 2 on the product application under review, all five procedural and not relating to data integrity.
- Manufacturing Pithampur, Jul-26, unannounced: two observations, procedural in nature and not relating to data integrity; response submitted in Jul-26, EIR awaited.
- Manufacturing Satara, Oct-26, unannounced: one observation, procedural in nature and not relating to data integrity.
What a Form 483 means, in simple terms
A Form 483 is the document in which the USFDA records observations made during an inspection of a facility. The company has said it is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner, and that it will keep the stock exchanges informed of any further updates on the subject.
Points a retail investor may want to track
- The company's response to the observations and how soon the evaluation is concluded.
- Whether an Establishment Inspection Report follows, as it has for the Canada, Thane and New Jersey facilities.
- The EIR awaited for the Pithampur facility, where a response was submitted in Jul-26.
- Any further update on the Satara facility, inspected in Oct-26 with one observation.
Context on the finding
The company has characterised all five Ambernath observations as procedural and unrelated to data integrity, and has stated that all its manufacturing and R&D facilities have now been inspected by the USFDA in the recent past.
Also from Rubicon Research
Earnings conference call scheduled for November 5 to discuss Q2 and H1 FY27 performance
28 Oct 2026
Board meeting on November 5 to consider and approve Q2 and H1 results
27 Oct 2026
US FDA issues Form 483 with 1 observation after unannounced inspection of Satara plant
9 Oct 2026
More numbers
- Observations on system improvement (Ambernath)3 observations
- Observations on product application under review (Ambernath)2 observations
- Total Form 483 observations at Ambernath5
- Observations at New Jersey facility (inspection under previous owner)Six Observations
- Observations at Pithampur facilityTwo Observations
- Observations at Satara facilityOne Observation
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.